TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy.
about
Maturation of morphology, phenotype and functions of murine bone marrow-derived dendritic cells (DCs) induced by polysaccharide Kureha (PSK).Combined TLR2/4-activated dendritic/tumor cell fusions induce augmented cytotoxic T lymphocytesAugmentation of antitumor immunity by fusions of ethanol-treated tumor cells and dendritic cells stimulated via dual TLRs through TGF-β1 blockade and IL-12p70 production.Protein-bound polysaccharide-K induces IL-1β via TLR2 and NLRP3 inflammasome activation.Preoperative administration of polysaccharide Kureha and reduced plasma transforming growth factor-β in patients with advanced gastric cancer: A randomized clinical trial.Immune Modulation From Five Major Mushrooms: Application to Integrative Oncology.Complete Spontaneous Regression of Merkel Cell Carcinoma Metastatic to the Liver: Did Lifestyle Modifications and Dietary Supplements Play a Role?Gamma delta T cells are activated by polysaccharide K (PSK) and contribute to the anti-tumor effect of PSK.VEGFR2 targeted antibody fused with MICA stimulates NKG2D mediated immunosurveillance and exhibits potent anti-tumor activity against breast cancerProtein-bound polysaccharide activates dendritic cells and enhances OVA-specific T cell response as vaccine adjuvantCancer cell-binding peptide fused Fc domain activates immune effector cells and blocks tumor growth.Combination strategies to enhance antitumor ADCC.Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30.Cross-talk between pathogen recognizing Toll-like receptors and immunoglobulin Fc receptors in immunity.Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells.Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host.Genotoxic stress modulates the release of exosomes from multiple myeloma cells capable of activating NK cell cytokine production: Role of HSP70/TLR2/NF-kB axis.Cetuximab combined with natural killer cells therapy: an alternative to chemoradiotherapy for patients with advanced non-small cell lung cancer (NSCLC).
P2860
Q34432604-47037ACE-B8FE-4F2C-9E83-77CABF633223Q34648926-70E20024-C608-4305-AE5D-AE62E772BD4BQ34744217-BEE02F72-89B6-4658-B847-126089F8BCA0Q35551792-82AF0213-B1D8-4619-A015-C713E098F10EQ35753818-82042C64-037A-46F1-813D-CDDC2F3C85A6Q36384392-32D78D81-1EC6-4C49-890D-22E829F48356Q36959667-6F13BEF5-9059-42C9-B114-67298CDEBEE9Q37056096-5DBE4FB9-149B-4E8F-9333-B112CEFA53E9Q37086056-77906A85-CB2B-4D21-BFE8-92DC224D1A27Q37198471-831334CE-F5CD-4D01-BE62-31E2FCE68F23Q37689046-EF2F857F-4CEF-429B-892F-116C1AF9CD78Q38014085-2F5DCEC3-A574-4C09-A5D5-F10B6BD2D736Q38563897-F2F929DB-99FE-4033-B05E-6CFBB23C21AFQ38615394-DE97515D-0DC3-4594-9351-9391C4593A4CQ39110347-9DB729E9-E389-4D34-9097-57AFCB132ECFQ48102534-F89F0E1F-1486-46AA-95FA-B5EF71F78E72Q52777089-A3A22AA7-1A9A-490A-9511-BBCFC024FFD1Q55005404-6C123BB9-2B90-4EBA-BBDC-6BDA102D9A56
P2860
TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy.
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
TLR2 agonist PSK activates hum ...... d monoclonal antibody therapy.
@ast
TLR2 agonist PSK activates hum ...... d monoclonal antibody therapy.
@en
type
label
TLR2 agonist PSK activates hum ...... d monoclonal antibody therapy.
@ast
TLR2 agonist PSK activates hum ...... d monoclonal antibody therapy.
@en
prefLabel
TLR2 agonist PSK activates hum ...... d monoclonal antibody therapy.
@ast
TLR2 agonist PSK activates hum ...... d monoclonal antibody therapy.
@en
P2093
P2860
P1476
TLR2 agonist PSK activates hum ...... d monoclonal antibody therapy.
@en
P2093
Carol Inatsuka
Cynthia A Wenner
Hailing Lu
Leanna J Standish
Mary L Disis
P2860
P304
P356
10.1158/1078-0432.CCR-11-1142
P407
P577
2011-09-14T00:00:00Z